
Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 165 716
B1

⑫

EUROPEAN PATENT SPECIFICATION

④⑤ Date of publication of patent specification: 31.01.90

⑦① Application number: 85303564.0

⑦② Date of filing: 21.05.85

⑤① Int. Cl.⁵: **G 01 N 33/534**,
G 01 N 33/60, **C 07 C 229/00**,
G 01 N 33/74, **G 01 N 33/94**

⑤④ Simultaneous multiple assays and compositions useful therein.

⑦③ Priority: 23.05.84 US 612979

④④ Date of publication of application:
27.12.85 Bulletin 85/52

④⑤ Publication of the grant of the patent:
31.01.90 Bulletin 90/05

⑦④ Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

⑤⑥ References cited:
EP-A-0 038 546
EP-A-0 068 875
EP-A-0 073 865
EP-A-0 103 558
GB-A-2 060 623
US-A-3 994 966

⑦⑤ Proprietor: ICN Micromedic Systems, Inc.
3300 Hyland Avenue
Costa Mesa, California 92626 (US)

⑦⑥ Inventor: Olson, Douglas Richard
4304 Salem Street R.D. No.2
Doylestown Pennsylvania 18901 (US)

⑦⑦ Representative: Votler, Sidney David et al
CARPMAELS & RANSFORD 43, Bloomsbury
Square
London WC1A 2RA (GB)

EP 0 165 716 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

Description

The present invention is concerned with simultaneous multiple assays and compositions useful therein. The simultaneous multiple assays may be carried out for organic species such as steroids, proteins, peptides, carbohydrates or drugs.

Radioimmunoassay is an analytical technique that resulted from the work of Berson and Yalow. In radioimmunoassay, radiolabelled exogenous antigen competes with unlabelled endogenous antigen for binding sites on an antibody or specific binding proteins, e.g. intrinsic factor, specific for the antigen.

The percentage of bound radiolabelled antigen decreases as a function of the increasing concentration of unlabelled antigen in the test sample. Separation of the bound and free radiolabelled antigen is necessary in order to determine the quantity of unlabelled antigen. This can be accomplished by insolubilization of the antigen-antibody complexes either by chemical means, e.g., polyethylene glycol precipitation, or by the addition of a second antibody directed toward the immunoglobulin present in the original antiserum, or by a combination of these two methods. The quantity of unlabelled antigen in an unknown sample is then determined by comparing the radioactivity of the precipitate, after centrifugation, with values established using known standards in the same assay system.

One aspect of this invention is concerned with simultaneous measurement of two or more organic species in the same tube wherein the material to be assayed is radiolabelled. It is also concerned with the preparation of the labelled organic species employing chelating agents.

There is a continuing search for cheaper and quicker analytical procedures. One way to accomplish this is to have an assay whereby two or more organic species can be assayed simultaneously in the same solution.

An example is in U.S. Patent No. 4,146,602 issued on March 27, 1979 which discloses a simultaneous assay of Folate and Vitamin B₁₂.

Co⁵⁷ is incorporated in Vitamin B₁₂ which is rather uncomplicated since Vitamin B₁₂ is a cobalt containing compound.

The problem was how to incorporate Co⁵⁷ into non-cobalt containing organic species.

Certain uses of chelating agents are well known; however, there is no known use of chelating agents to prepare radiolabelled organic species used in simultaneous assays.

A paper by Yeh et al. at pages 327—336 of *J. Radioanal. Chem.*, 53, (1979) describes the preparation of an assay of indium chelates. A chapter in the American Chemical Society publication *Advances in Chemistry Series. No. 198 Modification of Proteins* by Meares et al. at pages 369—387 discusses chelate tagged proteins and polypeptides using cobalt to prepare radiopharmaceuticals.

Egan et al at pages 611—613 of a paper entitled "⁵⁷Co: A Volume Mark for the TRIPLE-ISOTOPE, Double-Antibody Radioimmune Assay" in *Immunochemistry*, 1977, Vol. 14, discusses using a chelating agent (EDTA) with cobalt; but to prevent adsorption of cobalt to serum proteins.

EP—A—0068875 and GB—A—2060623 relate to the use of fluorescent labels and not to the use of radioisotopes. US—A—3994966 addresses the problem of providing radioactive labels which adhere to macromolecules. There is not the slightest suggestion that the compounds disclosed could be used in simultaneous multiple assays.

EP—A—0038546 addresses the problem of radio labelling biological molecules without degrading the molecules. EP—A—0073865 relates to a compound useful in determining the concentration of a thyroid hormone in a biological fluid.

We have now found that by employing chelating agents it is possible to label different organic species with different nuclides to provide a method for simultaneous assays on multiple organic species in a single tube.

Instruments are already being used to read radioactivity in a simultaneous assay (Vitamin B₁₂ and folate). Therefore, this invention will not require any new techniques or instrumentations.

The present invention relates to a composition containing a coordinated compound of the formula:

metal isotope—chelator—organic species.

An advantage of the composition of claim 1 is that the coordination compound provides the necessary flexibility for different nuclides to be used with different organic species, which is essential for simultaneous multiple assays.

Specifically, the present invention concerns a composition useful in a simultaneous assay comprising one (or preferably two) or more radioisotope labelled organic species in a solution, one or more of the species being a compound of the above formula and the radioisotope with which each species is labelled being different. The invention includes a composition useful in a simultaneous assay comprising one or more of the above coordinated compounds and an organic species labelled with I-125, and a simultaneous multiple assay using one or more of the above coordinated compounds.

The coordinated compound can conveniently be incorporated in a kit for use in simultaneous multiple assays of organic species.

By the use of this invention one can place a metal isotope on any suitable organic species, e.g. analyte, to assay for said organic species.

EP 0 165 716 B1

Another aspect is the metal isotope labelling of purified antibodies to said analyte(s) to construct an immunoradiometric assay (IRMA).

The essence of the invention is the introduction of radionuclides into organic species by way of organic species-bound chelating moieties and the subsequent use of the radio-labelled organic species in radioassays.

The chelators may be of a variety of materials satisfying the following criteria:

1) they must be capable of forming covalent linkages with the organic species of interest;
2) once attached to the organic species, they must retain their ability to form coordination complexes with +2 and +3 metal radionuclides; and

4) the formed complexes of organic species, chelator, and metal radionuclides must retain all or part of the binding specificity or antigenicity of the native organic species.

Radiolabelled organic species containing individually distinguishable radionuclides may be combined in a variety of configurations such that one or more organic species may be measured simultaneously by radioassay. Organic species labelled in this described manner could also be combined with organic species labelled by alternate means to provide simultaneous radioassays.

The choice of radionuclides to be utilized for labelling is governed by the following practical considerations.

1) they must have a sufficiently long half-life to enable them to be used over a practical period of time (eg. several months);

2) they must be available in sufficiently high specific activity to provide an adequate signal amplification; and

3) they must possess a distinguishable emission spectrum when used in combination with one or more other radionuclides.

The method of assaying comprises employing a coordinated compound of the general formula:



in a simultaneous multiple assay.

Examples of analytes which can be employed include any organic species which can react with a chelating agent. In general, they are steroids such as estrogens, progesterone, digoxin, cortisol, 17-hydroxyprogesterone and the like; proteins, such as human chorionic gonadotropin (HCG), leuteinizing hormone (LH), follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), alpha-fetoprotein, trypsin, hepatitis associated antigen, carcinoembryonic antigen and the like; peptides, such as ACTH, endorphins, angiotensin, insulin and the like; carbohydrates, such as pneumococcal polysaccharides and the like; drugs, such as cocaine, tetrahydrocannabinol, barbiturates, amphetamines and the like; antibiotics, such as gentamicin, and the like; also, the labeled antibodies to these analytes can be used.

Specific pairs of organic species which could be analyzed simultaneously include the following:

1. Carcinoembryonic Antigen (CEA β -hCG, α fetoprotein, or any other two tumor markers;

2. LH/FSH;

3. Hepatitis B Surface Antigen/Hepatitis B Core Antigen or any other two viral antigens;

4. Thyroxine (T_4)/Thyroid Stimulating Hormone in screening for neonatal hypothyroidism;

5. Thyroxine/Thyroid Binding Globulin (for T_3U , i.e. triiodothyronine uptake) in diagnosis and treatment of adult thyroid disease;

6. Angiotensin II/Renin in diagnosing cause for hypertension;

7. Adrenocorticotrophic Hormone (ACTH)/Cortisol in differentiating primary from secondary adrenal disease;


8. Insulin/C-Peptide in the diagnosis and treatment of diabetes;

9. Estriol/Human Placental Lactogen in monitoring pregnancy;

10. Lactate Dehydrogenase (LDH)/Creatine Phosphokinase (CPK) Isoenzymes in diagnosing heart disease; and

11. Serological Screening for Donor Blood for any two viruses or venereal infections simultaneously, such as hepatitis-B Surface Antigen and human T-Cell leukemia virus antigens or antibodies to same.

Chelating agents which can be used include aminopolycarboxylates of the following general formula:



wherein R^1 is hydrogen, phenyl or substituted phenyl wherein the substituents are NO_2 , NH_2 and/or SO_3H and the like and n is 0 or 1 such as ethylenediamine tetraacetic acid (EDTA), ethylene dinitrilotetraacetic acid, diethylenetriaminepentaacetic acid and derivatives thereof such as 1-(p -bromoacetimidobenzyl)-EDTA.

EP 0 165 716 B1

In general any radioisotope of a metal can be employed; however, practical considerations make it convenient to use only those with half lives of a reasonable period of time. However, it should be understood that even isotopes of a relatively short half life can be employed in this invention.

Preferred isotopes include those of the metals, cobalt, iron, indium, technetium, europium and terbium.

Especially preferred are isotopes of iron and cobalt with cobalt 57 and iron 59 being most preferred.

The labelled organic species may be prepared by reacting the chelating agent with the organic species at a temperature of from 4° to 40°C in a basic solution of a solvent such as sodium bicarbonate (0.1M).

After purification of the organic species, for example by passing the reaction mixture containing it through a molecular sieve, such as sephadex G75, or a polyacrylamide or other polymeric material acting as a molecular sieve, the treatment with the metal isotope at 4°C to 40°C can be carried out in the presence of a buffer from sodium acetate (metal free) or potassium acetate.

To obtain the best products of the invention the buffers should be metal-free if used in the preparation process.

The following examples illustrate the preparation of labelled organic species.

Example 1

Preparation of ⁵⁷Cobalt Labelled LH

One mg of lyophilized LH is dry mixed with 3.8 mg of diethylenetriamine pentaacetic anhydride (DTPA). 100 µl of metal-free 0.1M sodium bicarbonate is added and the reaction vortexed (metal free buffers are prepared by passing buffer solutions through metal chelating ion exchange resins such as BioRad Chelex 100). After thirty minutes at room temperature, the reaction mixture is passed through a Sephadex G75 column equilibrated and eluted with 0.5M acetate buffer pH 5.8 (metal free). The LH-DTPA containing fractions are identified by absorbance at 280 nm. Peak fractions are pooled and diluted to 100 µg LH/ml with 0.5M acetate buffer pH 5.8.

100 µl of LH-DTPA (10 µg) are added to 10 µl (500 µCi) of carrier-free ⁵⁷cobalt chloride in 0.5N HCl and reacted for one and one-half hours at room temperature. The reaction mixture is passed through a Sephadex G75 column equilibrated and eluted with phosphate buffered saline (PBS) containing 0.1% bovine albumin. The ⁵⁷Co-DTPA-LH elutes near the void volume as a single peak. In general >70% of the ⁵⁷Co is chelated by the LH-DTPA precursor yielding tracers with specific activities ranging from 36 to 43 µCi/µg.

Example 2

Preparation of ¹²⁵I Labelled FSH

This procedure describes the process for the preparation of FSH-I¹²⁵ tracer for an iodination size of 5 mCi, which will yield 2 to 2.5 mCi of usable tracer.

37.5 µl of FSH antigen at a concentration of 1 mg/ml in 0.01M PBS is added to a solution of 50 µl of 0.4M phosphate buffer, pH 7.4 and sodium I-125 (5 mCi) and vortexed. The reaction is initiated by the addition of 10 µl of chloramine-T (1 mg/ml 0.1M phosphate buffer, pH 7.2) to the reaction mixture and vortexed. The reaction is terminated after 25 seconds at room temperature by the addition of 25 µl of sodium metabisulfite (1 mg/ml in 0.1M phosphate buffer, pH 7.4) to the reaction mixture and vortexing.

Immediately after termination, the reaction mixture is transferred to a Sephadex G-75 column (0.5 x 18.0 cm) equilibrated in 0.01M PBS, 0.1% BSA. The column is eluted with 0.02M PBS/BSA and 0.5 ml fractions (bovine serum albumin (BSA)) are collected. The FSH I-125 elutes between fraction numbers 10 to 20. All fractions which are on the ascending and descending sides of the peak which contain greater than 40% of the activity of the peak tube are pooled. The pooled fractions are diluted with .01M PBS/BSA to a concentration of approximately 100 µCi/ml. The diluted tracer is treated with a 5 ml slurry of Bio-Rad AG-21K resin (rinsed and resuspended in 0.01M PBS, 3% BSA) and stored overnight at 4°C.

By substituting for the tracer organic species and chelating agent in Examples 1 and 2 and by following substantially the procedures described therein, the following radio-labelled tracers can be prepared.

EP 0 165 716 B1

Ex.	Tracer	Organic Species	Chelating Agent
3	⁵⁷ Co	LH	DTPA
4	⁵¹ Cr	FSH	DTPA
5	¹¹¹ In	TSH	phenyl EDTA
6	⁵⁷ Co	T ₄	DPTA
7	⁵⁷ Co	FSH	DPTA
8	⁵⁷ Co	TSH	phenyl EDTA
9	⁵⁷ Co	Ferritin	DTPA
10	⁵⁷ Co	Rabbit anti TSH	DTPA
11	⁵⁷ Co	TSH	DTPA

The following is an example of the types of hormones which can be employed in the assay procedure to be followed and the reagents which are required for the assay.

Organic Species

Luteinizing hormone (LH) and follicle stimulating hormone (FSH) are glycoproteins synthesized and secreted by the basophil (beta) cells of the anterior pituitary in response to gonadotropin releasing hormone (GnRH) produced by the hypothalamus. Both hormones consist of two polypeptide chains designated "alpha" and "beta". The amino acid sequence of the "alpha" subunits is similar for the two hormones as well as TSH and HCG. The "beta" subunits however, are unique and confer immunological specificity, biological specificity and biological activity for the two molecules.

In the female, LH and FSH regulate ovarian changes during the menstrual cycle. FSH promotes maturation of the Graafian follicle and ovum while LH is necessary for the development of a functioning corpus luteum and the production of progesterone. Circulating levels of LH and FSH are controlled by separate negative-feedback mechanisms on the hypothalamus.

In the male, FSH stimulates production of spermatozoa in the seminiferous tubules. Both FSH and LH promote testosterone secretion by the interstitial cells or Leydig tissue of the testes. Testosterone and other steroid hormones control circulating levels of LH and FSH by negative-feedback effects on the hypothalamus.

The measurement of LH and FSH is an important tool for evaluating disorders of the hypothalamic/pituitary/gonadal axis. Hypopituitarism due to pituitary dysfunction in both males and females may result in a hypogonadal state characterised by low levels of LH and FSH (hypogonadotropic hypogonadism). On the other hand, elevated levels of LH and FSH (hypergonadotropic hypogonadism) may indicate a hypogonadal state caused by primary gonadal failure although LH levels may be normal if androgen secretion is preserved.

In the female, the mid-cycle LH peak is a good indication that ovulation will occur within the next 24 hours. Thus, subfertile couples can be informed of impending ovulation. Such knowledge is also important in timing laparoscopy of oocyte retrieval and subsequent *in vitro* fertilization.

Reagents

LH COBALT 57 TRACER SOLUTION

LH tracer is prepared as described above and diluted to a concentration of approximately 0.02 µCi/ml in 0.01M PBS, 0.1% BSA, 5% normal rabbit serum and 0.1% sodium azide.

FSH ¹²⁵I TRACER SOLUTION

The FSH tracer solution is diluted in 0.01M PBS, 0.1% BSA, 5% normal rabbit serum, and ion exchange resin strip, and 0.1% sodium azide to a concentration of approximately 0.02 µCi/ml.

LH/FSH ANTISERUM SOLUTION

Each antisera is diluted in 0.01M PBS, 10 mM EDTA, 0.1% BSA, and 0.1% sodium azide at a titer sufficient to bind approximately 30% of the radiolabelled antigens.

EP 0 165 716 B1

LH/FSH PRECIPITATING SOLUTION

Goat anti-rabbit IgG immune serum is diluted in 0.01M PBS, 5% polyethylene glycol and 0.1% sodium azide at a titer sufficient to precipitate 100 microliters of 5% normal rabbit serum.

5 LH/FSH STANDARDS

Seven concentrations of LH/FSH standards, 0/0, 5/2.5, 10/5, 25/10, 60/25, 120/50, 240/100 mIU/mL are prepared in 0.01M PBS, 0.1% BSA, and 0.1% sodium azide.

10 LH/FSH CONTROLS

Control samples are prepared in 0.01M PBS, 0.1% BSA and 0.1% sodium azide.

Preparation of Reagents

Combine equal volumes of LH ⁵⁷Co tracer solution and FSH ¹²⁵I tracer solution. 50 µl of each tracer are required for each assay tube.

15

Specimen Collection and Preparation

Human serum or plasma samples should be used. If the assay is to be run on the day of specimen collection, store the sample at 4°C until assayed. If the assay is to be run at a later date, store sample frozen at -20°C. Allow the sample to thaw prior to assay; mix thoroughly. Heterogeneity of specimens after thawing has been shown to result in misleading assay values. The sample should be rejected for assay if it is radioactively contaminated from a previous *in vivo* diagnostic procedure. A fresh sample should be drawn after sufficient time has passed for the elimination of the radioactivity from the body.

20

Radioimmunoassay Procedure

25 Before proceeding with the assay, bring all reagents, sample and assay tubes to room temperature. A standard curve must be performed with each series of unknowns.

Generally, the assay procedure comprises admixing 200 µL of the standards, controls or patient sample with 100 µL of antiserum solution and then vortexing. The mixture is then incubated at 37°C for 60 minutes and thereafter 100 µL of tracer solution are added and the resultant mixture vortexed. After vortexing, the mixture is incubated at room temperature for 60 minutes, 1000 µL of precipitating solution are added and the mixture vortexed. After this vortexing the mixture is incubated at room temperature for 10 minutes and then centrifuged for 15 minutes at 1000 x g. The liquid is then decanted off and the remaining material is counted and the results noted.

30

More specifically, the assay procedure comprises:—

35

1. Label 12 x 75 mm assay tubes according to the following outline:

	ASSAY TUBE	CONTENTS
40	T,T	Total Counts
	1,2	Blank Tubes
	3,4	Standard:
	5,6	0 mIU/MI
		5 mIU/mL LH
		2.5 mIU/mL FSH
45	7,8	10 mIU/mL LH
		5 mIU/mL FSH
	9,10	25 mIU/mL LH
		10 mIU/mL FSH
	11,12	60 mIU/mL LH
50		25 mIU/mL FSH
	13,14	120 mIU/mL LH
		50 mIU/mL FSH
	15,16	240 mIU/mL LH
		100 mIU/mL LH
55	17,18	CI Control Sample
	19,20	CII Control Sample
	21,100	Patient Sample

55

2. Accurately pipette 200 µL of the ZERO STANDARD into the blank tubes and 200 µL of STANDARDS of patient samples into appropriately labelled assay tubes.
3. Pipette 100 µL of ANTISERUM SOLUTION into all tubes except Total Count and Blank tubes and vortex.
4. Incubate at 37°C for 1 hour.

65

EP 0 165 716 B1

5. Pipette 100 μ L of TRACER SOLUTION into all tubes and vortex.
6. Incubate at room temperature ($22 \pm 3^\circ\text{C}$) for 1 hour.
7. Shake the PRECIPITATING SOLUTION immediately before use. Pipette 1.0 mL into all tubes except total count tubes. Vortex tubes thoroughly.
8. Incubate at room temperature ($22 \pm 3^\circ\text{C}$) for 10 minutes.
9. Centrifuge for 15 minutes at $1000 \times g$.
10. Decant the liquid from each assay tube and blot rims of tubes on absorbent material.
11. Count tubes on gamma counter set respectively for I^{125} and Co^{57} for FSH and LH.

Procedural Notes

1. Establish a repetitive time pattern for addition of antibody, tracer, and precipitating antibody from the beginning to the end of the assay and for decantation.
 2. Be sure all droplets are removed from the rims after decanting.
 3. Consistent results occur between assays when a constant room temperature is maintained.
- NOTE: The gamma counter must discriminate adequately between I^{125} and Co^{57} . Counters that do not permit low crossover between channels or that do not offer adequate stability are unsatisfactory for this assay. Since the energy peaks of Co^{57} and I^{125} overlap, the windows of the gamma counter must be adjusted to assure $<3\%$ crossover. Do not omit this consideration as there is no proportionality in values obtained on an adjusted instrument and the accuracy of the test would be decreased.

$$\text{Using I-125 source: } \frac{\text{CPM from Co-57 channel}}{\text{CPM from I-125 channel}} \times 100 = \% \text{ crossover of I-125 into Co-57 channel}$$

$$\text{Using Co-57 source: } \frac{\text{CPM from I-125 channel}}{\text{CPM from Co-57 channel}} \times 100 = \% \text{ crossover of Co-57 into I-125 channel}$$

Calculation of Results

1. Average the counts per minute (CPM) for all duplicate tubes. Correct for nonspecific binding by subtracting the average CPM's of tubes 3 and 4 from all other counts.
2. Calculate the % Binding (B/Bo) by dividing the averaged CPM's for the standard and samples by the averaged CPM's of the ZERO STANDARD (tubes 5 and 6) and multiply by 100.

$$\text{Percent Binding (B/Bo)} = \frac{\text{CPM of Standard or Sample}}{\text{CPM of ZERO STANDARD}} \times 100$$

3. Prepare a standard curve on 3-cycle log-logit graph paper by:

- a) Plotting the percent binding (B/Bo) or averaged CPM for each standard concentration on the Y (logit or linear, ordinate) axis and the standard concentration values (mIU/ml LH or FSH) on the X (logarithmic, abscissa) axis.
- b) Draw a straight line through the data points. No attempt should be made to extrapolate the curve beyond the range employed.
4. Read the unknown patient samples from the standard curve (concentration is read off the X axis where patient CPM or % binding intersects the curve).

Typical raw data is shown in Table I.

TABLE I — Typical Data

Tube No.	Contents	LH		Patient Value mIU/ml	FSH		Value mIU/ml
		CPM Bound	Average Corrected CPM		CPM Bound	Average Corrected CPM	
1,2	Totals	90,410 90,576	86,927		67,802 67,808	67,805	
3,4	Assay Blank	3,750 3,548			1,962 1,816		
5,6	0	13,602 13,884	10,094	100	16,494 16,422	14,579	100
7,8	5/2.5	12,476 12,212	8,691	86.1	14,348 14,160	12,363	84.8
9,10	10/5	11,574 10,578	7,429	73.6	13,010 11,920	10,570	72.5
11,12	20/10	9,428 9,628	5,875	58.2	9,638 9,654	7,766	53.2
13,14	50/25	7,584 7,154	3,725	36.9	5,648 5,635	3,747	25.7
15,16	100/50	6,018 5,992	2,352	23.3	3,833 3,725	1,895	13.0
17,18	200/100	4,984 5,034	1,363	13.5	2,801 3,057	1,035	7.2
19,20	Control I	8,952 9,194	5,424	53.7	5,248 5,500	3,485	23.9
21,22	Control	7,678 7,680	4,030	39.9	9,930 10,484	8,318	57.1
							8.7

EP 0 165 716 B1

Expected Values (20—31) Normals

		LH mIU/ml	FSH mIU/ml
5	Female:		
	Follicular phase	0—14	2—10
	Mid-cycle peak	10—70	9—18
10	Luteal phase	0—16	0—9
	Post menopause	20—70	20—100
15	Male:	0—9	2—10

Published LH and FSH ranges may differ because of variations in calibration, method, and/or technique. Each laboratory must confirm its own normal range of a representative sample population.

Performance Characteristics

Precision is the extent to which a given set of measurements of the same sample agrees with the mean.

Results of Intra- and Inter-assay Variation

	LH Intra-Assay	LH Inter-Assay	FSH Intra-Assay	FSH Inter-Assay
25				
Pool 1				
X (mIU/ml)	19.4	19.4	6.2	6.2
30				
s (mIU/ml)	1.4	1.9	0.5	0.2
CV (%)	7.1	9.6	7.7	3.3
n	15	15	15	15
35				
m	3	3	3	3
Pool 2				
X (mIU/ml)	41.6	41.6	18.0	18.0
40				
s (mIU/ml)	2.1	2.5	0.9	1.0
CV (%)	5.0	6.1	5.2	5.5
45				
n	15	15	15	15
m	3	3	3	3
Pool 3				
50				
X (mIU/ml)	97.6	97.6	46.3	46.3
s (mIU/ml)	8.4	12.5	2.1	2.7
CV (%)	8.6	12.8	4.6	5.8
55				
n	30	30	30	30
m	6	6	6	6

Sensitivity

Sensitivity is the smallest amount of unlabelled antigen that can be distinguished from no antigen. The sensitivity of the assay is 1.7 mIU/ml for LH and 1.1 mIU/ml for FSH based on 95% B/Bo.

65

EP 0 165 716 B1

Accuracy

Accuracy is the extent to which a given measurement of a substance agrees with the known value of that substance.

5 (A) Spike Recovery

Two normal male base pools were spiked with five levels of LH and FSH. Results are shown on the following table:

10	LH/FSH added (mIU/ml)	LH		FSH	
		X Added Recovered (mIU/ml)	% LH Recovered	X Added Recovered (mIU/ml)	% FSH Recovered
15	10/5	12.2	122	6.3	127
	20/10	21.0	105	11.7	117
	40/20	41.7	104	21.6	108
20	80/40	83.4	104	46.1	115
	160/80	130.5	82	65.8	82

25 (B) Correlation with Other Methods

A patient sample correlation was run against three individual LH radioimmunoassays and three individual FSH radioimmunoassays. A least squares linear regression analysis was then carried out on paired values obtained in the LH and FSH RIA KIT procedure against each of the references. The results are summarized below:

30 LH: Method A = $0.949 + 1.8$
 $n = 28, r^2 = 0.918$
 Method B = $1.314 - 1.6$
 $n = 28, r^2 = 0.959$
 35 Method C* = $0.438 + 5.1$
 $n = 33, r^2 = 0.911$

* Standards for this method are calibrated against 2nd IRP-HMG. All other methods are calibrated against 1st IRP 68/40.

40 FSH: Method C = $1.045 - 2.8$
 $n = 23, r^2 = 0.893$
 Method D = $1.686 - 2.1$
 $n = 30, r^2 = 0.977$
 45 Method E** = $0.473 - 1.1$
 $n = 30, r^2 = 0.983$

** Standards for this method are calibrated against 2nd IRP-HMG. All other methods are calibrated against 1st IRP 69/194.

50 Specificity

Specificity is the extent of freedom from interference by substances other than the one intended to be measured. The degree of specificity of the antibody for the antigen represents one of the most significant advantages of any radioimmunoassay procedure.

55 The cross-reactivity of structurally similar hormones at fifty percent binding are given in the following table:

EP 0 165 716 B1

	COMPOUND	RELATIVE ACTIVITY*	
		LH ASSAY	FSH ASSAY
5	LH	1.000	<0.0035
	FSH	0.085	1.000
	HCG	0.261	<0.0028
10	TSH	<0.001	<0.0010

* Relative activity is calculated on a unit/unit basis except for TSH which is calculated on a weight/weight basis.

15 Chelex is a trade mark which may or may not be registered in all of the designated states.


Claims for the Contracting States: GB FR DE IT NL SE BE CH/LI LU

20 1. A composition useful in a simultaneous assay which comprises two or more radioisotope-labelled organic species in a solution, one or more of the organic species being coordinated compound(s) of the formula:

radioisotope—chelator—organic species

wherein the radioisotope with which each organic species is labelled is different.

25 2. A composition as claimed in claim 1 wherein the chelator of the one or more coordinated compounds is of the formula:



wherein R¹ is hydrogen, phenyl or substituted phenyl wherein the substituents are NO₂, NH₂ and/or SO₃H and n is 0 or 1, or a derivative thereof.

35 3. A composition as claimed in claim 2 wherein the chelator of the one or more coordinated compounds is ethylenediaminetetraacetic acid, ethylene dinitrilotetraacetic acid, diethylenetriaminepentaacetic acid, or a derivative thereof.

4. A composition as claimed in any of claims 1 to 3 wherein the radioisotope of the one or more coordinated compounds is cobalt, iron, technetium, europium, terbium or iodine.

40 5. A composition as claimed in any of claims 1 to 4 wherein the organic species of the one or more coordinated compounds is a steroid, a protein, a peptide, a carbohydrate or a drug.

6. A composition as claimed in claim 5 wherein the organic species of the one or more coordinated compounds is an estrogen, progesterone, digoxin, cortisol, 17-hydroxyprogesterone, human chorionic gonadotropin, leutinizing hormone, follicle stimulating hormone, thyroid stimulating hormone, alpha-feto-protein, trypsin, triiodothyronine, thyroxine, hepatitis associated antigen, carcinoembryonic antigen, 45 adrenocorticotrophic hormone, endorphins, angiotensin, insulin, pneumococcal polysaccharides, cocaine, tetrahydrocannabinol, a barbiturate, an amphetamine, gentamicin, Vitamin B₁₂ or folate.

7. A composition useful in a simultaneous assay which comprises two or more coordinated compounds as defined in any of claims 1 to 6, wherein the radioisotope with which each coordinated 50 compound is labelled is different.

8. A composition as claimed in claim 7 which comprises two of said coordinated compounds wherein:

(a) for the organic species of one of said coordinated compounds is used carcinoembryonic antigen and for the organic species of the other of said coordinated compounds is used β-hCG;

55 (b) for the organic species of one of said coordinated compounds is used leutinizing hormone and for the organic species of the other of said coordinated compounds is used thyroid stimulating hormone;

(c) for the organic species of one of said coordinated compounds is used hepatitis B-surface antigen and for the organic species of the other of said coordinated compounds is used hepatitis B-core antigen;

(d) for the organic species of one of said coordinated compounds is used thyroxine and for the organic species of the other of said coordinated compounds is used thyroid stimulating hormone;

60 (e) for the organic species of one of said coordinated compounds is used thyroxine and for the organic species of the other of said coordinated compounds is used thyroid binding globulin;

(f) for the organic species of one of said coordinated compounds is used angiotensin-II and for the organic species of the other of said coordinated compounds is used renin;

65 (g) for the organic species of one of said coordinated compounds is used adrenocorticotrophic hormone and for the organic species of the other of said coordinated compounds is used cortisol;

EP 0 165 716 B1

(h) for the organic species of one of said coordinated compounds is used insulin and for the organic species of the other of said coordinated compounds is used C-peptide;

(i) for the organic species of one of said coordinated compounds is used estriol and for the organic species of the other of said coordinated compounds is used human placental lactogen;

5 (j) for the organic species of one of said coordinated compounds is used lactate dehydrogenase and for the organic species of the other of said coordinated compounds is used creatine phosphokinase; or

(k) for the organic species of one of said coordinated compounds is used hepatitis B-surface antigen and for the organic species of the other of said coordinated compounds is used human T-cell leukemia virus.

10 9. A simultaneous multiple assay wherein one or more coordinated compounds as defined in any of claims 1 to 6 is/are employed.

10. A composition useful in a simultaneous assay which comprises one or more coordinated compounds as defined in any of claims 1 to 6 and an organic species labelled with I-125.

15 11. A composition as claimed in claim 10, wherein the coordinated compound organic species is leutinizing hormone and the organic species labelled with I-125 is follicle stimulating hormone.

12. A simultaneous multiple assay wherein there are employed one or more coordinated compounds of the formula:—

radioisotope—chelator—organic species

20 and an organic species labelled with I-125.

13. An assay as claimed in claim 12 wherein the coordinated compound organic species is leutinizing hormone and the organic species labelled with I-125 is follicle stimulating hormone.

14. A simultaneous multiple assay wherein a composition as claimed in any one of claims 1 to 8 is employed.

25


Claims for the Contracting State: AT

1. A method of forming composition useful in a simultaneous assay which comprises two or more radioisotope-labelled organic species in a solution, wherein a radioisotope, chelator and organic species are combined together to form one or more of the species, which one or more species is/are coordinated compound(s) of the formula:

radioisotope—chelator—organic species,

wherein the radioisotope with which each organic species is labelled is different.

35 2. A method as claimed in claim 1 wherein the chelator of the one or more coordinated compounds is of the formula:



wherein R¹ is hydrogen, phenyl or substituted phenyl wherein the substituents are NO₂, NH₂ and/or SO₃H and n is 0 or 1, or a derivative thereof.

45 3. A method as claimed in claim 2 wherein the chelator of the one or more compounds is ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, or a derivative thereof.

4. A method as claimed in any of claims 1 to 3 wherein the radioisotope of the one or more compounds is cobalt, iron, technetium, europium, terbium or iodine.

50 5. A method as claimed in any of claims 1 to 4 wherein the organic species of the one or more compounds is a steroid, a protein, a peptide, a carbohydrate or a drug.

6. A method as claimed in claim 5 wherein the organic species of the one or more compounds is an estrogen, progesterone, digoxin, cortisol, 17-hydroxyprogesterone, human chorionic gonadotropin, leutinizing hormone, follicle stimulating hormone, thyroid stimulating hormone, alpha-fetoprotein, trypsin, triiodothyronine, thyroxine, hepatitis associated antigen, carcinoembryonic antigen, adrenocorticotrophic hormone, endorphins, angiotensin, insulin, pneumococcal polysaccharides, cocaine, tetrahydrocannabinol, a barbiturate, an amphetamine, gentamicin, Vitamin B₁₂ or folate.

7. A method as claimed in any one of claims 1 to 6 wherein a radioisotope, chelator and organic species are combined to form two or more coordinated compounds of the formula:—

60

radioisotope—chelator—organic species,

wherein the radioisotope with which each organic species is labelled is different.

8. A method as claimed in claim 7 which comprises two of said coordinated compounds wherein:

65 (a) for the organic species of one of said coordinated compounds is used carcinoembryonic antigen and for the organic species of the other of said coordinated compounds is used β-hCG;

EP 0 165 716 B1

(b) for the organic species of one of said coordinated compounds is used leutinizing hormone and for the organic species of the other of said coordinated compounds is used thyroid stimulating hormone;

(c) for the organic species of one of said coordinated compounds is used hepatitis B-surface antigen and for the organic species of the other of said coordinated compounds is used hepatitis B-core antigen;

5 (d) for the organic species of one of said coordinated compounds is used thyroxine and for the organic species of the other of said coordinated compounds is used thyroid stimulating hormone;

(e) for the organic species of one of said coordinated compounds is used thyroxine and for the organic species of the other of said coordinated compounds is used thyroid binding globulin;

10 (f) for the organic species of one of said coordinated compounds is used angiotensin-II and for the organic species of the other of said coordinated compounds is used renin;

(g) for the organic species of one of said coordinated compounds is used adrenocorticotrophic hormone and for the organic species of the other of said coordinated compounds is used cortisol;

(h) for the organic species of one of said coordinated compounds is used insulin and for the organic species of the other of said coordinated compounds is used C-peptide;

15 (i) for the organic species of one of said coordinated compounds is used estriol and for the organic species of the other of said coordinated compounds is used human placental lactogen;

(j) for the organic species of one of said coordinated compounds is used lactate dehydrogenase and for the organic species of the other of said coordinated compounds is used creatine phosphokinase; or

20 (k) for the organic species of one of said coordinated compounds is used hepatitis B-surface antigen and for the organic species of the other of said coordinated compounds is used human T-cell leukemia virus.

9. A simultaneous multiple assay wherein one or more coordinated compounds of the formula:—

radioisotope—chelator—organic species

25 is/are employed.

10. A simultaneous multiple assay wherein there are employed one or more coordinated compounds of the formula:

radioisotope—chelator—organic species

30 and an organic species labelled with I-125.

11. An assay as claimed in claim 10 wherein the coordinated compound organic species is leutinizing hormone and the organic species labelled with I-125 is follicle stimulating hormone.

12. A simultaneous multiple assay as claimed in any of claims 9 to 11 wherein the coordinated compound(s) is/are prepared by a method as claimed in any of claims 2 to 8.

35 13. A method of performing a simultaneous multiple assay, comprising:

(I) incubating a solution containing

(a) two or more radioisotope-labelled organic species, one or more of which species is in the form of a coordinated compound of the general formula:

40 radioisotope—chelator—organic species,

wherein the radioisotope with which each organic species is labelled is different

(b) the two or more organic species, unlabelled, and

(c) compounds having binding sites specific to the two or more organic species,

45 (II) separating the bound and free organic species in the incubated solution,

(III) comparing the radioactivity of each bound organic species with values established using known standards in the same assay system and thereby determining the quantity of each unlabelled species.

14. A method as claimed in claim 13 characterised by one or more of the following:

(a) each organic species being in the form of a coordinated compound of the general formula:

50

radioisotope—chelator—organic species,

(b) the chelator being as defined in claim 2 or claim 3,

(c) the radioisotope being as defined in claim 4, and

55 (d) the organic species being as defined in any one of claims 5, 6 or 8,

or characterised by one or more of the following:

(e) the solution containing one or more labelled organic species in the form of a coordinated compound of the given general formula and a radioisotope-labelled organic species labelled with I-125,

60 (f) the solution containing leutinizing hormone in the form of a coordinated compound of the given general formula and follicle stimulating hormone labelled with I-125.

Patentansprüche für die Vertragsstaaten: GB FR DE IT NL SE BE CH LI LU

65 1. Zusammensetzung zur Verwendung in einem gleichzeitigen Assay, die zwei oder mehrere durch ein


EP 0 165 716 B1

Radioisotop gekennzeichnete organische Species in einer Lösung enthält, wobei eine oder mehrere der organischen Species (eine) koordinierte Verbindung(en) der Formel

Radioisotop – Chelator – organische Species

ist (sind), worin das Radioisotop, mit welchem jede organische Species gekennzeichnet ist, unterschiedlich ist.

2. Zusammensetzung nach Anspruch 1, in welcher der Chelator der einen oder mehreren koordinierten Verbindung(en) die Formel



in welcher R¹ für Wasserstoff, Phenyl oder substituiertes Phenyl steht, wobei die Substituenten NO₂, NH₂ und/oder SO₃H sind und n für 0 oder 1 steht, hat oder ein Derivat davon ist.

3. Zusammensetzung nach Anspruch 1, in welcher der Chelator der einen oder mehreren koordinierten Verbindung(en) Ethylendiaminotetraessigsäure, Ethylendinitrilotetraessigsäure, Diethylentriamino-pentaessigsäure oder ein Derivat derselben ist.

4. Zusammensetzung nach irgendeinem der Ansprüche 1 bis 3, in welcher das Radioisotop der einen oder mehreren koordinierten Verbindung(en) Cobalt, Eisen, Technetium, Europium, Terbium oder Jod ist.

5. Zusammensetzung nach irgendeinem der Ansprüche 1 bis 4, in welcher die organische Species der einen oder mehreren koordinierten Verbindung(en) ein Steroid, ein Protein, ein Peptid, ein Kohlenhydrat oder eine Droge ist.

6. Zusammensetzung nach Anspruch 5, in welcher die organische Species der einen oder mehreren koordinierten Verbindung(en) ein Östrogen, Progesteron, Digoxin, Cortisol, 17-Hydroxyprogesteron, humanes Choriongonadotropin, luteinisierendes Hormon, Follikel-stimulierendes Hormon, Thyroid-stimulierendes Hormon, alpha-Fetoprotein, Trypsin, Triiodothyronin, Thyroxin, Hepatitis-assoziiertes Antigen, carcinoembryonales Antigen, adrenocorticotrophes Hormon, Endorphin, Angiotensin, Insulin, Pneumococcal-Polysaccharid, Kokain, Tetrahydrocannabinol, ein Barbiturat, ein Amphetamin, Gentamicin, Vitamin B₁₂ oder Folat ist.

7. Zusammensetzung zur Verwendung in einem gleichzeitigen Assay, die zwei oder mehrere koordinierte Verbindungen gemäß der Definition in irgendeinem der Ansprüche 1 bis 6 enthält, wobei das Radioisotop, mit welchem jede koordinierte Verbindung gekennzeichnet ist, unterschiedlich ist.

8. Zusammensetzung nach Anspruch 7, die zwei der genannten koordinierten Verbindungen enthält, worin:

a) als organische Species der einen der genannten koordinierten Verbindungen carcinoembryonales Antigen und als organische Species der anderen der genannten koordinierten Verbindungen β-hCG verwendet wird;

b) als organische Species der einen der genannten koordinierten Verbindungen luteinisierendes Hormon und als organische Species der anderen der genannten koordinierten Verbindungen Thyroid-stimulierendes Hormon verwendet wird;

c) als organische Species der einen der genannten koordinierten Verbindungen Hepatitis B Oberflächenantigen und als organische Species der anderen der genannten koordinierten Verbindungen Hepatitis B Kernantigen verwendet wird;

d) als organische Species der einen der genannten koordinierten Verbindungen Thyroxin und als organische Species der anderen der genannten koordinierten Verbindungen Thyroid-stimulierendes Hormon verwendet wird;

e) als organische Species der einen der genannten koordinierten Verbindungen Thyroxin und als organische Species der anderen der genannten koordinierten Verbindungen Thyroid-bindendes Globulin verwendet wird;

f) als organische Species der einen der genannten koordinierten Verbindungen Angiotensin-II und als organische Species der anderen der genannten koordinierten Verbindungen Renin verwendet wird;

g) als organische Species der einen der genannten koordinierten Verbindungen adrenocorticotrophes Hormon und als organische Species der anderen der genannten koordinierten Verbindungen Cortisol verwendet wird;

h) als organische Species der einen der genannten koordinierten Verbindungen Insulin und als organische Species der anderen der genannten koordinierten Verbindungen C-Peptid verwendet wird;

i) als organische Species der einen der genannten koordinierten Verbindungen Estrinol und als organische Species der anderen der genannten koordinierten Verbindungen humanes Placenta-Lactogen verwendet wird;

j) als organische Species der einen der genannten koordinierten Verbindungen Lactat-Dehydrogenase und als organische Species der anderen der genannten koordinierten Verbindungen Kreatin-Phosphokinase verwendet wird; oder

5 k) als organische Species der einen der genannten koordinierten Verbindungen Hepatitis B Oberflächenantigen und als organische Species der anderen der genannten koordinierten Verbindungen humanes T-Zellen-Leukämie-Virus verwendet wird.

9. Simultaner mehrfacher Assay, bei welchem eine oder mehrere koordinierte Verbindung(en), die in irgendeinem der Ansprüche 1 bis 6 definiert ist (sind) verwendet wird (werden).

10 10. Zusammensetzung nach Verwendung in einem simultanen Assay, die eine oder mehrere koordinierte Verbindung(en), die in irgendeinem der Ansprüche 1 bis 6 definiert ist (sind), und eine mit 1-125 gekennzeichnete organische Species enthält.

11. Zusammensetzung nach Anspruch 10, in welcher die organische Species der koordinierten Verbindung luteinisierendes Hormon und die mit 1-125 gekennzeichnete organische Species Follikel-stimulierendes Hormon ist.

16 12. Simultaner mehrfacher Assay, in welchem eine oder mehrere koordinierte Verbindungen der Formel

Radioisotop—Chelator—organische Species

und eine mit I-125 gekennzeichnete organische Species verwendet werden.

20 13. Assay nach Anspruch 12, in welchem die organische Species der koordinierten Verbindung luteinisierendes Hormon und die mit I-125 gekennzeichnete organische Species Follikel-stimulierendes Hormon ist.

14. Gleichzeitiger mehrfacher Assay, in welchem eine Zusammensetzung nach irgendeinem der Ansprüche 1 bis 8 verwendet wird.


25 Patentansprüche für den Vertragsstaat: AT

30 1. Verfahren zur Herstellung einer Zusammensetzung zur Verwendung in einem gleichzeitigen Assay, die zwei oder mehrere durch ein Radioisotop gekennzeichnete organische Species in einer Lösung enthält, wobei ein Radioisotop, ein Chelator und eine organische Species miteinander verbunden sind, um eine oder mehrere der Species zu bilden, von denen eine oder mehrere (eine) koordinierte Verbindung(en) der Formel

Radioisotop—Chelator—organische Species

35 ist (sind), worin das Radioisotop, mit welchem jede organische Species gekennzeichnet ist, unterschiedlich ist.

2. Verfahren nach Anspruch 1, bei welchem der Chelator der einen oder mehreren koordinierten Verbindung(en) die Formel



45 in welcher R¹ für Wasserstoff, Phenyl oder substituiertes Phenyl steht, wobei die Substituenten NO₂, NH₂ und/oder SO₃H sind und n für 0 oder 1 steht, hat oder ein Derivat davon ist.

3. Verfahren nach Anspruch 1, bei welchem der Chelator der einen oder mehreren Verbindung(en) Ethyldiaminotetraessigsäure, Diethylentriaminopentaessigsäure oder ein Derivat derselben ist.

4. Verfahren nach irgendeinem der Ansprüche 1 bis 3, bei welchem das Radioisotop der einen oder mehreren Verbindung(en) Cobalt, Eisen, Technetium, Europium, Terbium oder Jod ist.

50 5. Verfahren nach irgendeinem der Ansprüche 1 bis 4, bei welchem die organische Species der einen oder mehreren Verbindung(en) ein Steroid, ein Protein, ein Peptid, ein Kohlenhydrat oder eine Droge ist.

6. Verfahren nach Anspruch 5, bei welchem die organische Species der einen oder mehreren Verbindung(en) ein Steroid, ein Protein, ein Lipid, ein Kohlenhydrat oder eine Pflanze, ein Tier oder ein Mensch ist.

7. Verfahren nach Anspruch 5, bei welchem die organische Species der einen oder mehreren Verbindung(en) ein Östrogen, Progesteron, Digoxin, Cortisol, 17-Hydroxyprogesteron, humanes Choriongonadotropin, luteinisierendes Hormon, Follikel-stimulierendes Hormon, Thyroid-stimulierendes Hormon, alpha-Fetoprotein, Trypsin, Triiodothyronin, Thyroxin, Hepatitis-assoziiertes Antigen, carcinoembryonales Antigen, adrenocorticotrophes Hormon, Endorphin, Angiotensin, Insulin, Pneumococcon-Polysaccharid, Kokain, Tetrahydrocannabinol, ein Barbiturat, ein Amphetamin, Gentamicin, Vitamin B₁₂ oder Folat ist.

7. Verfahren nach irgendeinem der Ansprüche 1 bis 6, bei welchem ein Radioisotop, ein Chelator und eine organische Species kombiniert werden, um zwei oder mehrere koordinierte Verbindungen der Formel

Radioisotop – Chelator – organische Species

zu bilden, in welcher das Radioisotop mit dem jede organische Species gekennzeichnet ist, unterschiedlich ist.

EP 0 165 716 B1

8. Verfahren nach Anspruch 7, das zwei der genannten koordinierten Verbindungen umfaßt, worin:
- a) als organische Species der einen der genannten koordinierten Verbindungen carcinoembryonales Antigen und als organische Species der anderen der genannten koordinierten Verbindung β -hCG verwendet wird;
 - 5 b) als organische Species der einen der genannten koordinierten Verbindungen luteinisierendes Hormon und als organische Species der anderen der genannten koordinierten Verbindungen Thyroid-stimulierendes Hormon verwendet wird;
 - c) als organische Species der einen der genannten koordinierten Verbindungen Hepatitis B Oberflächenantigen und als organische Species der anderen der genannten koordinierten Verbindungen Hepatitis B Kernantigen verwendet wird;
 - 10 d) als organische Species der einen der genannten koordinierten Verbindungen Thyroxin und als organische Species der anderen der genannten koordinierten Verbindungen Thyroid-stimulierendes Hormon verwendet wird;
 - e) als organische Species der einen der genannten koordinierten Verbindungen Thyroxin und als
15 organische Species der anderen der genannten koordinierten Verbindungen Thyroid-bindendes Globulin verwendet wird;
 - f) als organische Species der einen der genannten koordinierten Verbindungen Angiotensin-II und als organische Species der anderen der genannten koordinierten Verbindungen Renin verwendet wird;
 - g) als organische Species der einen der genannten koordinierten Verbindungen adrenocorticotrophes
20 Hormon und als organische Species der anderen der genannten koordinierten Verbindungen Cortisol verwendet wird;
 - h) als organische Species der einen der genannten koordinierten Verbindungen Insulin und als organische Species der anderen der genannten koordinierten Verbindungen C-Peptid verwendet wird;
 - i) als organische Species der einen der genannten koordinierten Verbindungen Estriol und als
25 organische Species der anderen der genannten koordinierten Verbindungen humanes Placenta-Lactogen verwendet wird;
 - j) als organische Species der einen der genannten koordinierten Verbindung Lactat-Dehydrogenase und als organische Species der anderen der genannten koordinierten Verbindungen Kreatin-Phosphokinase verwendet wird; oder
 - 30 k) als organische Species der einen der genannten koordinierten Verbindungen Hepatitis B Oberflächenantigen und als organische Species der anderen der genannten koordinierten Verbindungen humanes T-Zellen-Leukämie-Virus verwendet wird.
9. Simultaner mehrfacher Assay, bei welchem eine oder mehrere koordinierte Verbindung(en) der Formel
- 35 Radioisotop—Chelator—organische Species
- verwendet wird (werden).
10. Simultaner mehrfacher Assay, bei welchem eine oder mehrere koordinierte Verbindungen der Formel
- 40 Radioisotop—Chelator—organische Species
- und eine mit I-125 gekennzeichnete organische Species verwendet werden.
11. Assay nach Anspruch 10, bei welchem die organische Species der koordinierten Verbindung luteinisierendes Hormon und die mit I-125 gekennzeichnete organische Species Follikel-stimulierendes
45 Hormon ist.
12. Simultaner mehrfacher Assay nach irgendeinem der Ansprüche 9 bis 11, bei welchem die koordinierte(n) Verbindung(en) nach einem Verfahren nach irgendeinem der Ansprüche 2 bis 8 hergestellt ist (sind).
13. Verfahren zur Durchführung eines simultanen mehrfachen Assays, bei welchem:
- 50 (I) eine Lösung inkubiert wird, die enthält
- (a) zwei oder mehrere mit einem Radioisotop gekennzeichnete organische Species, von denen eine oder mehrere in Form einer koordinierten Verbindung der allgemeinen Formel
- Radioisotop—Chelator—organische Species
- 55 vorliegt, wobei das Radioisotop, mit dem jede organische Species gekennzeichnet ist, unterschiedlich ist,
- (b) die beiden oder mehreren organischen Species, ungekennzeichnet, und
- (c) Verbindungen mit Bindungsstellen, die für die beiden oder mehreren organischen Species spezifisch sind,
- 60 (II) Trennung der gebundenen und freien organischen Species in der inkubierten Lösung
- (III) Vergleich der Radioaktivität jeder gebundenen organischen Species mit Werten, die unter Verwendung bekannter Standards in dem gleichen Assay-System erstellt wurden, und dabei Bestimmung der Menge jeder ungekennzeichneten Species.
14. Verfahren nach Anspruch 13, gekennzeichnet durch ein oder mehrere der folgenden Merkmale:
- 65 (a) jede organische Species liegt in Form einer koordinierten Verbindung der allgemeinen Formel

EP 0 165 716 B1

Radioisotop—Chelator—organische Species

vor

- (b) der Chelator entspricht der in Anspruch 2 oder Anspruch 3 gegebenen Definition
 (c) das Radioisotop entspricht der Definition von Anspruch 4 und
 5 (d) die organische Species entspricht der Definition nach irgendeinem der Ansprüche 5, 6 oder 8 oder gekennzeichnet durch ein oder mehrere der folgenden Merkmale;
 (e) die Lösung enthält eine oder mehrere gekennzeichnete organische Species in Form einer koordinierten Verbindung der gegebenen Formel und eine mit I-125 Radioisotop-gekennzeichnete organische Species,
 10 (f) die Lösung enthält luteinisierendes Hormon in Form einer koordinierten Verbindung der gegebenen allgemeinen Formel und mit I-125 gekennzeichnetes Follikel-stimulierendes Hormon.

Revendications pour les Etats contractants: GB FR DE IT NL SE BE CH LI LU

- 15 1. Composition utile dans un essai de dosages simultanés, la composition comprenant deux ou plus de deux espèces organiques marquées par un radio-isotope, dans une solution, une ou plusieurs des espèces organiques étant un ou des composés coordonnés de formule:


radio-isotope—chélateur—espèce(s) organique(s)

20

dans le(s)quel(s) le radio-isotope avec lequel chaque espèce organique est marquée, est différent.

2. Composition telle que revendiquée à la revendication 1, dans laquelle le chélateur du ou des composés coordonnés répond à la formule:

25



30

dans laquelle R¹ représente un atome d'hydrogène, un groupe phényle ou phényle substitué dans lequel les substituants sont NO₂, NH₂ et/ou SO₃H, et n vaut 0 ou 1, ou est un dérivé du composé ci-dessus.

3. Composition telle que revendiquée à la revendication 2, dans laquelle le chélateur d'un ou plusieurs composés coordonnés est l'acide éthylènediaminetétraacétique, l'acide éthylènedinitrilotétraacétique, l'acide diéthylènetriaminépentaacétique, ou un de leurs dérivés.

- 35 4. Composition telle que revendiquée dans l'une quelconque des revendications 1 à 3, dans laquelle le radioisotope du ou des composés coordonnés est le cobalt, le fer, le technétium, l'euprotium, le terbium ou l'iode.

- 40 5. Composition telle que revendiquée dans l'une quelconque des revendications 1 à 4, dans laquelle l'espèce organique du ou des composés coordonnés est un stéroïde, une protéine, un peptide, un glucide (ou hydrate de carbone) ou un produit médicinal.

- 45 6. Composition telle que revendiquée à la revendication 5, dans laquelle l'espèce organique du ou des composés coordonnés est un oestrogène, le progestérone, la digoxine, le cortisol, la 17-hydroxy-progestérone, la gonadotropine de chorion humain, une hormone de lutéinisation, une hormone de stimulation des follicules, l'hormone de stimulation de la thyroïde, une alpha-fétoprotéine, de la trypsine, la triiodothyronine, la thyroxine, un antigène associé à l'hépatite, un antigène carcinoembryon, l'hormone adrénocorticotrope, des endorphines, l'angiotensine, l'insuline, des polysaccharides de pneumocoques, de la cocaïne, le tétrahydrocannabinol, un barbiturique une amphotamine, la gentamicine, la vitamine B₁₂ ou du folate.

- 50 7. Composition utile dans un dosage simultané, qui comprend deux ou plusieurs composés coordonnés selon la définition donnée dans l'une quelconque des revendications 1 à 6, et dans lesquels le radio-isotope avec lequel chaque composé coordonné est marqué est différent.

8. Composition telle que revendiquée à la revendication 7, qui comprend deux desdits composés coordonnés, dans lesquels:

- 55 (a) comme espèce organique de l'un desdits composés coordonnés, on utilise de l'antigène carcino-embryonnaire et, comme espèce organique de l'autre desdits composés coordonnés, on utilise le bêta-hCG;
 (b) comme espèce organique de l'un desdits composés coordonnés, on utilise l'hormone de lutéinisation et, comme espèce organique de l'autre desdits composés coordonnés, on utilise l'hormone de stimulation de la thyroïde;

- 60 (c) comme espèce organique de l'un desdits composés coordonnés, on utilise un antigène de surface d'hépatite B et, comme espèce organique de l'autre desdits composés coordonnés, on utilise l'antigène de partie centrale ou noyau d'hépatite B;

- 65 (d) comme espèce organique de l'un des composés coordonnés, on utilise de la thyroxine et, comme espèce organique de l'autre desdits composés coordonnés, on utilise l'hormone de stimulation de la thyroïde;

EP 0 165 716 B1

(e) comme espèce organique de l'un desdits composés coordonnés, on utilise la thyroxine et, comme espèce organique de l'autre desdits composés coordonnés, on utilise une globuline se fixant sur la thyroïde;

(f) comme espèce organique de l'un desdits composés coordonnés, on utilise l'angiotensine-II et, comme espèce organique de l'autre desdits composés coordonnés, on utilise la rénine;

5 (g) comme espèce organique de l'un desdits composés coordonnés, on utilise l'hormone adrénocorticotrophique et, comme espèce organique de l'autre desdits composés coordonnés, on utilise le cortisol;

(h) comme espèce organique de l'un desdits composés coordonnés, on utilise l'insuline et, comme espèce organique de l'autre desdits composés coordonnés, on utilise le peptide C;

10 (i) comme espèce organique de l'un desdits composés coordonnés, on utilise l'oestriol et, comme espèce organique de l'autre desdits composés coordonnés, on utilise du lactogène de placenta humain;

(j) comme espèce organique de l'un desdits composés coordonnés, on utilise la lactate déshydrogénase et, comme espèce organique de l'autre desdits composés coordonnés, on utilise la créatine phosphokinase; ou

15 (k) comme espèce organique de l'un desdits composés coordonnés, on utilise l'antigène de surface d'hépatite D et, comme espèce organique de l'autre desdits composés coordonnés, on utilise le virus de leucémie humaine à cellules T.

9. Dosages multiples simultanés, dans lesquels on utilise un ou plusieurs composés coordonnés tels que définis dans l'une quelconque des revendications 1 à 6.

20 10. Composition utile dans des dosages simultanés, qui comprend un ou plusieurs composés coordonnés tels que définis dans l'une quelconque des revendications 1 à 6 et une espèce organique marquée par I—125.

11. Composition telle que revendiquée à la revendication 10, dans laquelle l'espèce organique coordonnée est de l'hormone de lutéinisation, et l'espèce organique marquée par I—125 est une hormone de stimulation des follicules.

25 12. Dosages multiples simultanés, dans lesquels on utilise un ou plusieurs composés coordonnés de formule:

radio-isotope—chélateur—espèce(s) organique(s)

et une espèce organique marquée par I—125.

30 13. Dosages tels que revendiqués à la revendication 12, dans lequel l'espèce organique du composé coordonné est de l'hormone de lutéinisation, et l'espèce organique marquée par I—125 est de l'hormone de stimulation des follicules.

14. Dosages multiples simultanés, dans lesquels on utilise une composition telle que revendiquée dans l'une quelconque des revendications 1 à 8.


35 **Revendications pour l'Etat contractant: AT**

1. Procédé pour former une composition utile dans un essai de dosages simultanés, qui comprend deux ou plusieurs espèces organiques marquées par du radio-isotope dans une solution, dans lequel on combine ensemble un radio-isotope, un chélateur et une espèce organique pour former une ou plusieurs des espèces, cette ou ces espèces étant un ou des composés coordonnés de formule:

radio-isotope—chélateur—espèce(s) organique(s),

45 le radio-isotope avec lequel chaque espèce organique est marquée étant différent.

2. Procédé tel que revendiqué à la revendication 1, dans lequel le chélateur de l'un ou de plusieurs composés coordonnés répond à la formule:



55 dans laquelle R¹ représente un atome d'hydrogène, un groupe phényle ou phényle substitué dans lequel les substituants sont NO₂, NH₂ et/ou SO₃H et n vaut 0 ou 1, ou un dérivé.

3. Procédé tel que revendiqué à la revendication 2, dans lequel le chélateur du ou de plusieurs composés est l'acide éthylènediaminetétraacétique, l'acide diéthylènetriaminepentaacétique, ou un de leurs dérivés.

60 4. Procédé tel que revendiqué dans l'une quelconque des revendications 1 à 3, dans lequel le radio-isotope de l'un ou de plusieurs composés est le cobalt, le fer, le technétium, l'euprium, le terbium ou l'iode.

65 5. Procédé tel que revendiqué dans l'une quelconque des revendications 1 à 4, dans lequel l'espèce organique du ou de plusieurs composés est un stéroïde, une protéine, un peptide, un glucide (ou hydrate de carbone) ou un composé médicinal.

EP 0 165 716 B1

6. Procédé tel que revendiqué à la revendication 5, dans lequel l'espèce organique du ou des composés est un oestrogène, la progestérone, la digoxine, le cortisol, la 17-hydroxyprogestérone, la gonadotropine de chorion humain, une hormone de lutéinisation, une hormone de stimulation de follicules, l'hormone de stimulation de la thyroïde, l'alpha-fétoprotéine, la trypsine, la triiodothyronine, la thyroxine, un antigène associé à de l'hépatite, un antigène carcinoembryonnaire, l'hormone adrénocorticotrope, des endorphines, de l'angiotensine, l'insuline, des polysaccharides de pneumocoque, la cocaïne, le tétrahydrocannabinol, un barbiturique, une amphétamine, la getamicine, la vitamine B₁₂ ou un folate.

7. Procédé tel que revendiqué dans l'une quelconque des revendications 1 à 6, dans lequel on combine un radio-isotope, un chélateur et de l'espèce organique pour former deux ou plusieurs composés coordonnés de formule:

radio-isotope—chélateur—espèce(s) organique(s),

le radio-isotope avec lequel chaque espèce organique est marquée étant différent.

8. Procédé tel que revendiqué à la revendication 7, qui comprend deux desdits composés coordonnés, dans lequel:

(a) comme espèce organique de l'un desdits composés coordonnés, on utilise de l'antigène carcinoembryonnaire et, comme espèce organique de l'autre desdits composés coordonnés, on utilise le bêta-hCG;

(b) comme espèce organique de l'un desdits composés coordonnés, on utilise l'hormone de lutéinisation et, comme espèce organique de l'autre desdits composés coordonnés, on utilise l'hormone de stimulation de la thyroïde;

(c) comme espèce organique de l'un desdits composés coordonnés, on utilise antigène de surface de d'hépatite B et, comme espèce organique de l'autre desdits composés coordonnés, on utilise l'antigène de partie centrale ou de noyau d'hépatite B;

(d) comme espèce organique de l'un desdits composés coordonnés, on utilise de la thyroxine et, comme espèce organique de l'autre desdits composés coordonnés, on utilise l'hormone de stimulation de la thyroïde;

(e) comme espèce organique de l'un desdits composés coordonnés, on utilise la thyroxine et, comme espèce organique de l'autre desdits composés coordonnés, on utilise une globuline se fixant sur la thyroïde;

(f) comme espèce organique de l'un desdits composés coordonnés, on utilise l'angiotensine-II et, comme espèce organique de l'autre desdits composés coordonnés, on utilise la rénine;

(g) comme espèce organique de l'un desdits composés coordonnés, on utilise l'hormone adrénocorticotrope et, comme espèce organique de l'autre desdits composés coordonnés, on utilise le cortisol;

(h) comme espèce organique de l'un desdits composés coordonnés, on utilise de l'insuline et, comme espèce organique de l'autre desdits composés coordonnés, on utilise du peptide C;

(i) comme espèce organique de l'un desdits composés coordonnés, on utilise l'oestriol et, comme espèce organique de l'autre desdits composés coordonnés, on utilise du lactogène de placenta humain;

(j) comme espèce organique de l'un desdits composés coordonnés, on utilise la lactate déshydrogénase et, comme espèce organique de l'autre desdits composés coordonnés, on utilise la créatine phosphokinase; ou

(k) comme espèce organique de l'un desdits composés coordonnés, on utilise l'antigène de surface d'hépatite B et, comme espèce organique de l'autre desdits composés coordonnés, on utilise le virus de leucémie humaine à cellules T.

9. Dosages multiples simultanés, dans lequel on utilise un ou plusieurs composés coordonnés de formule:

radio-isotope—chélateur—espèce(s) organique(s)

10. Dosages multiples simultanés, dans lesquels on utilise un ou plusieurs composés coordonnés de formule:

radio-isotope—chélateur—espèce(s) organique(s)

et une espèce organique marquée par I-125.

11. Dosage tel que revendiqué à la revendication 10, dans lequel l'espèce organique du composé coordonné est de l'hormone de lutéinisation et l'espèce organique marquée par I-125 est de l'hormone de stimulation des follicules.

12. Dosages multiples simultanés, tel que revendiqués dans l'une quelconque des revendications 9 à 11, dans lequel le ou les composés coordonnés est ou sont préparés par un procédé tel que revendiqué dans l'une quelconque des revendications 2 à 8.

13. Procédé pour effectuer des dosages multiples simultanés, comprenant:

(i) l'incubation d'une solution contenant:

(a) deux ou plus de deux espèces organiques marquées par du radio-isotope, une ou plusieurs de ces espèces étant sous la forme d'un composé coordonné de formule générale:

radio-isotope—chélateur—espèce(s) organique(s),

le radio-isotope avec lequel chaque espèce organique est marquée étant différent,

EP 0 165 716 B1

(b) les deux ou plus de deux espèces organiques, non marquées, et
(c) des composés ayant des sites de liaison spécifiques à l'égard des deux ou plus de deux espèces organiques,

6 (II) la séparation de l'espèce organique liée et de l'espèce organique libre dans la solution résultant de l'incubation,

(III) une comparaison de la radio-activité de chaque espèce organique liée avec des valeurs établies en utilisant des étalons connus dans le même système de dosage et, ainsi, la détermination de la quantité de chaque espèce non marquée.

10 14. Procédé tel que revendiqué à la revendication 13, caractérisé par une ou plusieurs des particularités suivantes:

(a) chaque espèce organique est sous la forme d'un composé coordonné de formule générale:

radio-isotope—chélateur—espèce(s) organique(s),

15 (b) le chélateur est tel que défini à la revendication 2 ou la revendication 3,

(c) le radio-isotope est tel que défini à la revendication 4, et

(d) l'espèce organique est telle que définie dans l'une quelconque des revendications 5, 6 ou 8, ou procédé caractérisé par une ou plusieurs des particularités suivantes:

20 (e) la solution contient une ou plusieurs espèces organiques marquées, sous forme d'un composé coordonné répondant à la formule générale indiquée, et une espèce organique marquée par le radio-isotope I—125,

(f) la solution contient de l'hormone de lutéinisation sous forme d'un composé coordonné répondant à la formule générale donnée ci-dessus et de l'hormone de stimulation des follicules, marquée par I—125.

25

30

35

40

45

50

55

60

65

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.